| Acquired by | GlaxoSmithKline |
| Price | $3.6B |
| Date | 4/09 |
| Terms | Cash and Stock |
| Website | stiefel.com |
| Category | BioTech |
| Phone | 305-443-3800 |
| Employees | |
| Description | Dermatology Pharmaceuticals |
Stiefel Laboratories,Inc works to advance dermatology and skin science around the world. The company’s deeply-rooted dedication and drive for innovation along with its sole focus on dermatology has led Stiefel to become the largest independent dermatology company in the world. In addition to more than 30 wholly-owned subsidiaries, six manufacturing plants and a global research and development network, Stiefel’s most valuable asset is its global network of nearly 3,500 driven associates.
By combining expertise, knowledge and imagination, Stiefel delivers exceptional ethical, over-the-counter and aesthetic products to its customers in more than 100 countries around the world, ultimately providing a unique Stiefel skin health experience. Stiefel is also committed to improving today’s treatments and exploring tomorrow’s innovations. Each year, the company invests more than $100 million in developing the most advanced skin health solutions.
